A series of preliminary Mayo Clinic studies conducted in 2010 showed promise for the potential use of a chemical component of green tea (epigallocatechin gallate) in reducing the number of cancer cells in patients with chronic lymphocytic leukemia. (businessinsider.com)
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. (thno.org)
Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy. (cancernetwork.com)